Marengo Therapeutics Secures Second FDA Fast Track Designation for Invikafusp Alfa, Broadening Its Scope to High Tumor Mutational Burden Solid Tumors #USA #Cambridge #FDA_Fast_Track #Marengo_Therapeutics #Invikafusp_Alfa

Innovative Cancer Treatment Results Announced for Invikafusp Alfa and TRODELVY® at SITC 2026 #United_States #Phoenix #Marengo_Therapeutics #Invikafusp_Alfa #Trodelvy

Marengo Therapeutics Completes Enrollment in Phase 1/2 STARt-001 for Cancer Immunotherapy #USA #Cambridge #Marengo_Therapeutics #Invikafusp_Alfa #STARt-001